- Home
- DYAI vs ANTX Comparison
DYAI vs ANTX Comparison
Compare DYAI & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- ANTX
- Stock Information
- Founded
- DYAI 1979
- ANTX 2017
- Country
- DYAI United States
- ANTX United States
- Employees
- DYAI N/A
- ANTX N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- DYAI Health Care
- ANTX Health Care
- Exchange
- DYAI Nasdaq
- ANTX Nasdaq
- Market Cap
- DYAI 28.3M
- ANTX 33.2M
- IPO Year
- DYAI 2004
- ANTX 2022
- Fundamental
- Price
- DYAI $0.97
- ANTX $1.07
- Analyst Decision
- DYAI Strong Buy
- ANTX Buy
- Analyst Count
- DYAI 1
- ANTX 2
- Target Price
- DYAI $6.00
- ANTX $2.00
- AVG Volume (30 Days)
- DYAI 62.4K
- ANTX 254.6K
- Earning Date
- DYAI 08-12-2025
- ANTX 08-12-2025
- Dividend Yield
- DYAI N/A
- ANTX N/A
- EPS Growth
- DYAI N/A
- ANTX N/A
- EPS
- DYAI N/A
- ANTX N/A
- Revenue
- DYAI $3,554,344.00
- ANTX N/A
- Revenue This Year
- DYAI $22.56
- ANTX N/A
- Revenue Next Year
- DYAI $30.95
- ANTX N/A
- P/E Ratio
- DYAI N/A
- ANTX N/A
- Revenue Growth
- DYAI 57.59
- ANTX N/A
- 52 Week Low
- DYAI $0.91
- ANTX $0.87
- 52 Week High
- DYAI $2.20
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- DYAI 48.24
- ANTX 45.67
- Support Level
- DYAI $0.91
- ANTX $1.05
- Resistance Level
- DYAI $1.01
- ANTX $1.11
- Average True Range (ATR)
- DYAI 0.05
- ANTX 0.04
- MACD
- DYAI 0.01
- ANTX 0.00
- Stochastic Oscillator
- DYAI 40.00
- ANTX 33.33
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.